miR-23b and miR-218 (microRNA-23b and microRNA-218) (miR-23b; miR-218)

miR-23b and miR-218 are small, endogenous microRNAs that regulate gene expression by binding to complementary sequences in target mRNAs, leading to transcript degradation or translational repression. Both molecules have been identified as tumor suppressors in various cancers and have additive or synergistic effects in modulating critical cancer-related processes, including cell proliferation, migration, invasion, apoptosis, and angiogenesis[1][3][4]. In neuromuscular disease, specifically myotonic dystrophy type 1, inhibition of both miR-23b and miR-218 restores the levels of Muscleblind-like proteins and corrects defective RNA splicing[2]. Both microRNAs are of therapeutic interest as their modulation can alter pathological states, but their ubiquitous roles in gene regulation warrant caution regarding unintended biological effects. Note: "miR-23b and miR-218" is not a single target but refers to two distinct microRNAs that may be studied together for their potential combined regulatory effects in certain biological or disease contexts.

Other names

microRNA-23bmicroRNA-218miR-23b-3pmiR-218-5p

Antagonists (antagomirs) bind and inhibit miR-23b and miR-218, leading to de-repression of their target genes such as MBNL1/2 and reversal of pathological missplicing